skip to search skip to navigation skip to main content

News

Early detection is key to increase the survival rate of prostate cancer patients

03rd May 2017 in Product Launches

7% of the Egyptian male population are within the age group at risk for prostate cancer[1] Egyptian men who are diagnosed with prostate cancer are 7.2 times more likely to die from the disease as compared with the USA[2] Astellas Pharma launched Xtandi™ – enabling physicians to better tailor prostate cancer disease management according to…

Read Full Post

Astellas to Acquire Ogeda SA

05th April 2017 in Mergers & Acquisitions

Acquisition expands Astellas’ late stage clinical pipeline with Fezolinetant Tokyo, Japan and Gosselies, Belgium, April 3, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ogeda SA (CEO:Jean Combalbert, ”Ogeda”) announced today that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire…

Read Full Post

Suffering from ‘got to go now’ feeling – UroGuide launched to offer support to overactive bladder (OAB) patients

12th March 2017 in Other activities

UroGuide and OAB Awareness campaign has been launched to address lack of bladder disease awareness UroGuide is available for download from Lebanese Urology Society website  Failing to seek medical advice results in patients suffering unnecessarily with the burdens of OAB Beirut, 3rd March 2017. Lebanese Urology Society in partnership with Astellas Pharma have developed and…

Read Full Post

GenomeDx Announces Research Collaboration with Astellas to Identify Genomic Drivers of Patient Response to XTANDI® (enzalutamide) Capsules

13th February 2017 in Other activities

San Diego, January 2017 – Astellas in collaboration with GenomeDx Biosciences announced that it has entered into a research collaboration to apply genomic tumor profiling using GenomeDx’s Decipher® Classifier and Decipher GRID® as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI® (enzalutamide). As…

Read Full Post

Astellas Reports the First Nine Months Financial Results of FY2016

31st January 2017 in Other activities

Astellas Pharma Inc. (TOKYO: 4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for three quarters of fiscal year 2016 ending March 31, 2017 (“FY2016”). “We achieved many milestones including the acquisition of Ganymed Pharmaceuticals, a Germany-based pharma company, last December. The acquisition of Ganymed will enable Astellas to further expand its oncology…

Read Full Post

Astellas Announces Transfer of Qutenza™ to Grünenthal

13th December 2016 in Mergers & Acquisitions

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma Europe”) has entered into a definitive agreement with Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa…

Read Full Post

Patients in Egypt can now benefit from a new first-in-class overactive bladder treatment

24th November 2016 in Product Launches

More than 500 million people around the world are affected by OAB[1] Around 40% of the OAB patients are silent sufferers and have never consulted a physician about their condition[2] Urinary dysfunction should not be considered as natural part of ageing  Astellas Pharma – World category leader in Urology- launches BETMIGA in Egypt  Cairo, Egypt;…

Read Full Post

Astellas Pharma launched its hormonal prostate cancer treatment in three-month dosing

10th November 2016 in Product Launches

More than 11% of the Iranian male population are within the risk age group for prostate cancer [1] Men in the Middle East region are approximately 3 times more likely to die from prostate cancer as compared with the Northern Europe [2] Early detection is more likely to increase the survival rate of prostate cancer…

Read Full Post

Prostate Cancer screening is vitally important for Jordan’s male population over 50

08th November 2016 in Product Launches

More than 8% of the Jordanian male population are within the risk age group for prostate cancer[1] Early detection may increase overall survival rate Currently men in Jordan are 5.3 times more likely to die from prostate cancer as compared with the USA[2] Astellas Pharma launched its prostate cancer treatment Xtandi™ providing effective disease treatment…

Read Full Post

Astellas to Acquire Ganymed Pharmaceuticals

28th October 2016 in Mergers & Acquisitions

Tokyo and Mainz, October 28, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for…

Read Full Post

Privacy Policy  |  Terms of Use Copyright © 2017 Astellas Pharma